Oscar Health, Inc.
No enriched coverage for $OSCR in the last 7 days.
No SEC Form 4 filings for $OSCR in the last 30 days.
Oscar Health CEO Mark T. Bertolini recently purchased 1,000,000 shares of Class A Common Stock for $11.92 million. While the stock has seen an 11% return, the company recently reported wider-than-expected losses for Q4 2025. Despite financial misses, Raymond James upgraded Oscar Health's stock to Outperform, citing attractive relative valuation and recovering margins.
Oscar Health (OSCR) recently received an Outperform upgrade from Raymond James, driven by expectations of margin expansion in the Affordable Care Act exchange market and improved administrative efficiency. Despite recent share price fluctuations, the stock is trading at an approximately 18% discount to the analyst price target of US$15.40, with a fair value estimated at $15.78, suggesting it is undervalued. The increased fair value is attributed to updated pricing work, benefit design, and resilient exchange enrollment, though policy changes and industry consolidation remain potential risks.
While the technology sector is gradually showing some signs of recuperation - particularly with the cryptocurrency ecosystem finding recent momentum - skepticism remains a major source of anxiety. One name that has apparently aroused suspicion is Microsoft Corp ( NASDAQ:MSFT ) .
